Remove Hospital Remove Radiation Remove Radiopharmaceuticals
article thumbnail

ARRS: How to manage the side effects of radiopharmaceuticals

AuntMinnie

Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer. Extravasations Extravasations, in particular, are of interest to the U.S.

article thumbnail

The rise of theranostics: Part 5 -- Advice from center administrators

AuntMinnie

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Reshaping the hospital's nuclear medicine and radiopharmaceutical strategy toward theranostics involves intensive and inclusive planning, Beyder explained at SNMMI.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

IMV: PET scan volumes continue to grow

AuntMinnie

In terms of 2023 spending, the average radiopharmaceutical expenditure per fixed PET site is estimated to be $517,000. In 2023, 38% of PET systems were operated by the PET department, 28% by nuclear medicine, 24% by radiology/imaging, 5% by radiation oncology, and 2% by molecular imaging.

PET Scan 290
article thumbnail

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

article thumbnail

Meet the Minnies 2024 finalists

AuntMinnie

Louis School of Medicine and completed his residency and a neuroradiology fellowship at Massachusetts General Hospital in Boston. She currently serves as chair of the department of medical imaging and radiation sciences in the College of Health Professions at TJU and directs the radiography and invasive cardiovascular technology programs.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

article thumbnail

Imaging societies' reactions mixed on finalized MPFS, HOPPS rules

AuntMinnie

Centers for Medicare & Medicaid Services (CMS) 2025 Medicare Physician Fee Schedule (MPFS) and Hospital Outpatient Prospective Payment System (HOPPS) final rules. The American Society for Radiation Oncology (ASTRO) was disappointed in the final MPFS rule. Although the 2025 MPFS calls for an overall 2.9% This is a huge win for U.S.